TRPV2 and triple-negative breast carcinoma: Considering the aggressive nature of triple negative breast cancer (TNBC) and its limited therapeutic options, we proceeded to elucidate the tumorigenic effect of TRPV2 in vivo by injecting the TNBC cell line MDA-MB-231 cells with control vector, shTRPV2-1, or shTRPV2-2 vector into Balb/c nude mice.